SCYL1 and lobular neoplasia: In silico analysis of upstream regulators, downstream kinases and drug signatures for the identification of novel therapeutic targets in LN: Kinases TRRAP, AKT2, CDK16 and SCYL1 as putative targets for reversing the LN signature